Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors.

被引：27
作者：
Ichinose M. [1 ]
Masuoka J. [1 ]
Shiraishi T. [1 ]
Mineta T. [1 ]
Tabuchi K. [1 ]
机构：
[1] Department of Neurosurgery, Saga Medical School, Nabeshima
来源：
Brain Tumor Pathology | 2001年 / 18卷 / 1期
关键词：
Astrocytic tumor; TIL; Fas ligand; apoptosis;
D O I：
10.1007/BF02478923
中图分类号：
学科分类号：
摘要：
Fas (APO-1/CD95) ligand (FasL) and its receptor, Fas, play a key role in the regulation of apoptosis in the immune system. FasL acts as a cytotoxic effector molecule to Fas-expressing malignant tumor cells; however, it has recently been suggested that FasL also acts as a possible mediator of tumor immune privilege. We studied FasL expression in glioblastoma cell lines and a series of human glioma specimens by Western blotting and immunohistochemistry. In addition, quantitative analysis of T-cell infiltration in these tumors was performed. FasL expression was seen in all cell lines and in 9 of 14 specimens by Western blotting and immunohistochemistry. The distribution of FasL was recognized in the cytoplasm of tumor cells (5 of 9) and in the vascular endothelium (4 of 9). Both types of FasL expression were associated with a significant reduction (p < 0.05) in T-cell infiltration when compared with FasL-negative areas within the same tumor or FasL-negative specimens. Since T-cell apoptosis could be induced by FasL-expressing tumor cells, the present findings suggest that apoptosis induction by FasL expressed on tumor cells and/or vascular endothelium might be one mechanism for T-cell depletion in astrocytic tumor tissues.
引用
收藏
页码：37 / 42
页数：5
相关论文
共 86 条
[11]  
Brunner T(1997)Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99 1173-1178
[12]  
Fletcher SM(1998)The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma J Immunol 160 5669-5675
[13]  
Bellgrau D(1995)Expression of the functional soluble form of human Fas ligand in activated lymphocytes EMBO J 14 1129-1135
[14]  
Gold D(1996)Fas ligand in human serum Nature Med 2 317-322
[15]  
Selawry H(1990)JC70, a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections J Clin Pathol 43 752-757
[16]  
O'Connell J(1998)TNFα regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation Nature Med 4 415-420
[17]  
O'Sullivan GC(1995)Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias Blood 85 1562-1569
[18]  
Collins JK(1995)Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett 94 1-8
[19]  
Hahne M(1995)Expression of Fas/APO-1 during the progression of astrocytomas Cancer Res 55 5528-5530
[20]  
Rimildi D(1995)Resistance to Fasmediated apoptosis in human hepatoma cells Oncogene 11 1157-1164
123456789